SR9009 Reference

Plain English

What it is

SR9009 (also called Stenabolic) is a lab-made compound that switches on a body-clock and metabolism protein called REV-ERB. It is not an androgen muscle-building SARM, even though it is sold and grouped with them. It is sold only as a research chemical, not an approved medicine.

What people use it for

In the bodybuilding and fitness community, people talk about it for endurance, fat loss, and body recomposition, often paired with cardarine. Those uses are based on personal stories, not on any approved or proven benefit.

What the science shows

Almost all of the research is preclinical, done in mice and in lab dishes, not in people. In the foundational studies the compound was given to mice by injection, and the audited notes say it is poorly absorbed when swallowed, so pills likely deliver very little into the body. There are no human trials showing it works.

The catch

The U.S. FDA has warned the public against SARMs and SARM-type bodybuilding products, which are often sold illegally and mislabeled, and the FDA links that category to serious harms such as liver injury and a higher risk of heart attack or stroke; FDA enforcement applies to SR9009 even though it is a REV-ERB agent and not a true androgen SARM. WADA also bans it in sport at all times as a metabolic modulator (category S4.5). Because it has never been properly tested in people, its real safety in humans is unknown.

Reference summary

Published work is preclinical, focused on REV-ERBα agonism and circadian / metabolic phenotypes in rodents. Oral bioavailability of SR9009 is poor; community oral use likely produces little systemic exposure.

Regulatory and posture

Categories

SARM, Fat Loss

Aliases

Stenabolic, REV-ERBα agonist, Non-SARM

Evidence posture

preclinical - Not a SARM - REV-ERBα agonist. Oral bioavailability is poor; community framing as an exercise mimetic outruns the published evidence. WADA-prohibited under category S4.5 hormone and metabolic modulators at all times. FDA enforcement attention.

Regulatory status

No FDA-approved SR9009 drug label. WADA prohibits SR9009 under category S4.5 hormone and metabolic modulators at all times. FDA enforcement against SARMs sellers applies even though SR9009 is technically a REV-ERBα agonist, not a SARM. Oral bioavailability of SR9009 is poor in published rodent literature.

Content review status

research reference